Virtu Financial LLC Takes Position in Tempest Therapeutics, Inc. (NASDAQ:TPST)

Virtu Financial LLC purchased a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 43,105 shares of the company’s stock, valued at approximately $36,000.

Separately, XTX Topco Ltd purchased a new position in Tempest Therapeutics in the third quarter valued at about $34,000. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Stock Down 3.2 %

Shares of NASDAQ:TPST opened at $0.71 on Wednesday. The firm has a market capitalization of $31.19 million, a PE ratio of -0.47 and a beta of -1.83. The company has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $0.97. Tempest Therapeutics, Inc. has a twelve month low of $0.70 and a twelve month high of $6.00.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07). The company had revenue of $0.49 million for the quarter. Analysts anticipate that Tempest Therapeutics, Inc. will post -1.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TPST. Scotiabank decreased their price target on shares of Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating for the company in a research note on Friday, March 28th. HC Wainwright decreased their target price on Tempest Therapeutics from $47.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, March 28th.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.